China’s CMT To Buy HPV Diagnostics From Firm For $345 Million
This article was originally published in PharmAsia News
China Medical Technologies says it has bought from a diagnostics maker the rights to market a human papillomavirus detection system for $345 million. The system consists of a biosensor chip for HPV-DNA able to identify 24 common strains. The chip was developed by Molecular Diagnostic Technologies, which has agreed to sell the technology to China Medical around the end of the year. China estimate 30 percent of the 120 million Chinese women who should have tests for cervical cancer would need HPV tests, a business it figures could reach $700 million a year. (Click here for more
You may also be interested in...
US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.
Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.